Frontierby eninvs

Language: EN · RU

← Region

Genomma Lab Internacional (LAB) USD

At a glance: strengths & risks
✓Low leverage (0.5x EBITDA)✗Revenue declining (-6%)

Sector: Consumer health

MX_LAB

Price chart

13.51 MXNDay -0.22%

Key metrics

Net debt (table and EV/EBITDA): |short-term borrowings| + |long-term borrowings| + |other financial liabilities| when extracted + |non-controlling interest| when extracted − |cash and equivalents|; amounts in millions of the reporting currency.

Market

Price
13.51 MXN · -0.22%
Market cap
780 mln USD

Growth

Δ revenue y/y
9.2%
Δ EBITDA y/y
4.8%

Multiples

P/E (LTM)
8.9x
3y avg: 14.8x
P/B (FY)
1.3x
P/E (ann.)
7.0x
EV/EBITDA (LTM)
4.9x
3y avg: 5.7x
EV/EBITDA (ann.)
4.9x

Cash return

Dividend yield
5.9%
FCF yield (LTM)
-20.1%

Value creation

fundamental value/yr, % of market cap
Value created / year
-42.9%
↓ details

Liquidity

Daily turnover (listing)
45.1 mln MXN

Shares: yahoo_fundamentals_timeseries/LABB.MX

Amounts: USD (converted) · As reported
Converted modes use NBK / ECB-linked rates: balance sheet date for BS items, period average for P&L and cash flow (see filing row evidence). As reported keeps each row in its filing currency.

Financial results

Monetary columns are in M USD, one decimal; scale (K/M/B/T) keeps values readable. For the period (default) shows P&L and cash flow for that row’s reporting window: quarterly amounts when the feed uses quarter-duration facts (typical US 10-Q revenue and income), quarterly cash flows after stripping YTD where only cumulative tags exist, and an implied Q4 on 31 Dec FY rows (P&L: FY minus Q1–Q3; operating / investing cash flow: FY 12m minus 9M YTD to 30 Sep when sourced from SEC builder evidence) so they match 10-Q scale. Some issuers still use cumulative YTD minus the prior row in the same calendar year. As reported shows values stored on each row (e.g. full-year on FY). Balance sheet is always as reported. Source JSON may use millions etc.; conversion uses amounts_unit per row.

DatePeriodStatusRevenueM USDOperating profitM USDD&AM USDEBITDAM USDNet profitM USDOperating CFM USDCapex + M&AM USDAssetsM USDEquityM USDROE (annualized)Net debtM USDSource
2026-03-31Q1 2026 (3M)OK236.0
y/y 9.2%
49.2
y/y 4.5%
5.1
y/y 7.3%
54.3
y/y 4.8%
27.9
y/y 13.9%
-12.9-4.51376.9
y/y 16.6%
650.4
y/y 19.4%
17.6%291.4Report (PDF)
2025-12-31FY 2025 (12M)OK—
y/y -10.3%
—
y/y -8.5%
—
y/y 0.3%
—
y/y -7.8%
—
y/y 2.8%
——1326.1
y/y 19.5%
618.2
y/y 17.8%
13.9%107.3Link
2025-06-30Q2 2025 (3M)OK239.4
y/y —
52.8
y/y —
4.7
y/y —
57.5
y/y —
18.2
y/y —
26.1-0.81286.3
y/y —
596.1
y/y —
12.7%-137.3Report (PDF)
2025-03-31Q1 2025 (3M)OK216.1
y/y —
47.1
y/y —
4.8
y/y —
51.9
y/y —
24.5
y/y —
-7.4-4.41180.4
y/y —
544.6
y/y —
18.3%-105.7Report (PDF)
2024-12-31FY 2024 (12M)OK1022.0
y/y 10.3%
214.5
y/y 19.1%
19.8
y/y 54.5%
234.3
y/y 21.5%
82.0
y/y 42.1%
166.6-37.11109.7
y/y -9.2%
524.7
y/y -5.2%
15.2%134.5Link
2023-12-31FY 2023 (12M)OK—
y/y —
—
y/y —
—
y/y —
—
y/y —
—
y/y —
——1221.5
y/y —
553.8
y/y —
10.2%161.4Link
2023-03-31Q1 2023 (3M)OK222.1
y/y —
42.7
y/y —
0.0
y/y —
42.7
y/y —
19.0
y/y —
——1209.6
y/y —
574.7
y/y —
—0.0Report (PDF)

Net debt structure (leases included, IFRS 16) 2026-03-31

Short-term debt (incl. ST leases)185
Long-term debt (incl. LT leases)263
− Cash & equivalents156
Net debt291

Net debt / LTM EBITDA: 1.4x

Revenue & EBITDA

RevenueEBITDA

Quarterly values ($ mln)

02505007501 0002023 q12024 FY2025 q12025 q22026 q1

Year-over-year change

0%2%5%8%10%2023 q12024 FY2025 q12025 q22026 q1

Cash flow

FCF ($ mln)

-500501001502023 q12024 FY2025 q12025 q22026 q1

Net debt / cash ($ mln)

-200-10001002003002023 q12023 q42024 FY2025 q12025 q22025 q42026 q1

Profit and cash

Profit is cash-backed
In a typical year of 2023–2025 operating cash flow came to 2.03x of reported net profit.
year202320242025
cash flow / profit2.19x2.03x1.27x
accruals, % of assets-5.9%-6.7%-1.8%
Last twelve months (to - Q1 2025): 1.23x of profit came back as operating cash flow.
net debt / EBITDA 0.5x
Read from the reported annual statements: cash flow / profit is the median of the yearly operating cash flow over net profit for the years shown; accruals are (profit − operating cash flow) / assets, the classic gap between what was booked and what was collected. A gap can be growth in working capital, capitalised costs, revaluations or profit from associates — the panel points at it, the statements explain it. Not investment advice.

Fundamental value creation

Value the company creates per year, as a % of market cap

Value created per year: -42.4%

How this was calculated
1. EBITDA growth (latest quarter YoY, annualised)
[EBITDA latest qtr − EBITDA year-ago qtr] × annualisation X (2026-03-31 vs 2025-03-31)
= (54 − 52) × 3.80
9
2. Current EV/EBITDA (LTM)
(Market cap + Net debt) ÷ EBITDA (LTM)
= (780 + 291) ÷ 206
5.2x
3. Target multiple
(Current EV/EBITDA + 9) ÷ 2
= (5.2 + 9) ÷ 2
7.1x
4. Cash flow (balance method, LTM)
Net-debt reduction + dividends + buybacks − equity issuance
= -397 + 0 + 0 − 0
-397
5. Value created per year
(EBITDA growth × Target multiple + Cash flow − Dilution) ÷ Market cap
= (9 × 7.1 + -397) ÷ 780
-42.4%

Amounts in millions of the reporting currency. EBITDA growth is the latest quarter vs the same quarter a year ago, annualised.

Caveats:

  • capex unavailable — FCF approximated by FY OCF
  • dividends/buybacks not in data - balance cash flow uses net-debt change only

Revenue growth & acceleration

Growth decelerating ▼
Last-year revenue growth -6% vs +13% the year before — a -18.7 pp move. 3-year CAGR —.
revenue growth by year: 2024 +13% · 2025 -6%
The growth-acceleration signal behind the GARP+acceleration strategy — it favours companies whose revenue growth is speeding up and flags those slowing down (the second derivative of growth).

Dividends

Paid (completed)

DatePer shareDetailsStatusSource
2026-06-260.2 MXNEx-dividend: 0.2 MXN per sharePaidYahoo Finance (ex-div)
2026-03-300.2 MXNEx-dividend: 0.2 MXN per sharePaidYahoo Finance (ex-div)
2025-12-230.2 MXNEx-dividend: 0.2 MXN per sharePaidYahoo Finance (ex-div)
2025-09-180.2 MXNEx-dividend: 0.2 MXN per sharePaidYahoo Finance (ex-div)
2025-06-300.2 MXNEx-dividend: 0.2 MXN per sharePaidYahoo Finance (ex-div)
2025-03-130.2 MXNEx-dividend: 0.2 MXN per sharePaidYahoo Finance (ex-div)
2024-12-170.2 MXNEx-dividend: 0.2 MXN per sharePaidYahoo Finance (ex-div)
2024-09-130.2 MXNEx-dividend: 0.2 MXN per sharePaidYahoo Finance (ex-div)
2024-06-200.2 MXNEx-dividend: 0.2 MXN per sharePaidYahoo Finance (ex-div)
2024-03-210.1961 MXNEx-dividend: 0.1961 MXN per sharePaidYahoo Finance (ex-div)
2023-12-220.1961 MXNEx-dividend: 0.1961 MXN per sharePaidYahoo Finance (ex-div)
2023-09-280.1961 MXNEx-dividend: 0.1961 MXN per sharePaidYahoo Finance (ex-div)
2023-06-050.1961 MXNEx-dividend: 0.1961 MXN per sharePaidYahoo Finance (ex-div)
2022-11-090.3817 MXNEx-dividend: 0.3817 MXN per sharePaidYahoo Finance (ex-div)
2022-06-060.3817 MXNEx-dividend: 0.3817 MXN per sharePaidYahoo Finance (ex-div)
2021-12-080.3817 MXNEx-dividend: 0.3817 MXN per sharePaidYahoo Finance (ex-div)
2021-12-010.7634 MXNEx-dividend: 0.7634 MXN per sharePaidYahoo Finance (ex-div)

KASE: status follows wording in the news headline (paid vs intends to pay). Yahoo: amounts are cash dividends per share on ex-dividend dates (UTC calendar date). stockscope.uz (UZ): amounts are per share in UZS by publication date (not necessarily ex-div).

Investor reporting (IR): https://inversionistas.genommalab.com/en/investors/

Reporting forms detected in loaded periods: ✓ ✓ ✓ (Balance sheet / Profit or loss (P&L) / Cash flows)

Financial results, valuation multiples (P/E, P/B, EV/EBITDA), profitability and dividend yield of Genomma Lab Internacional (LAB) — from primary filings.

Genomma Lab is a pharmaceutical and consumer-health company focused on OTC drugs, personal care and branded generics in Mexico and abroad.

Frequently asked questions

What is Genomma Lab Internacional (LAB)'s P/E ratio?
Genomma Lab Internacional (LAB) trades at a P/E of 8.9x (price to trailing 12-month earnings).
What is Genomma Lab Internacional (LAB)'s EV/EBITDA?
Genomma Lab Internacional (LAB) trades at 4.9x EV/EBITDA.
What is Genomma Lab Internacional (LAB)'s P/B ratio?
Genomma Lab Internacional (LAB) trades at a P/B of 1.3x.
What is Genomma Lab Internacional (LAB)'s dividend yield?
Genomma Lab Internacional (LAB)'s trailing 12-month dividend yield is 5.9%.
What is Genomma Lab Internacional (LAB)'s return on equity (ROE)?
Genomma Lab Internacional (LAB)'s ROE is 17.6%.
What is Genomma Lab Internacional (LAB)'s market capitalization?
Genomma Lab Internacional (LAB)'s market cap is 780 mln USD.

See also: Mexican Stocks (2026): Quality Value and the Nearshoring Trade · The Cheapest Stocks in the World (2026): What Value Investing Says About Buying Cheap · global valuation map